Brochure
12 Jul 2023
Affiliate Partner ASM Research Chemicals Commercially Launches Development Packs for API Manufacturing
PDF 93 kB
A press release covering the launch of affiliate ASM Research Chemicals new service development, "Devpacks". The service was developed and optimized across ten core partners to establish a standardized and robust dataset of development process steps. Now fully optimized and streamlined, the DevPack service is commercially available to help overcome resource bottlenecks and streamline API research, development, troubleshooting, and scale-up activities.
Content provided by our supplier
C2pharma
-
Country/Region:Ireland
-
On CPHI since:2015
-
Employees:25 - 49
Company types
Other Content from C2pharma (20)
-
News Logistics4Pharma Expands Customs Services with Temporary Storage & Transit Document Management
They have recently expanded their customs Storage and Transit Document Management. With a complete customs service portfolio near Frankfurt International Airport, Logistics4Pharma provides fast and reliable customs solutions, enhancing flexibility and efficiency for global supply chains.
-
Video Ophthlamic Buyers Guide x PharmaSource
As the global leader in Ophthalmic APIs, C2 PHARMA was asked to participate in Pharmasource’s buyer guide focused on Ophthalmics. -
News C2 PHARMA receives CEP approval for Oxybuprocaine Hydrochloride
C2 PHARMA, the global leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the approval of a Certificate of Suitability (CEP) for Oxybuprocaine Hydrochloride by the European Directorate for the Quality of Medicines and Health Care (EDQM). Oxybuprocaine Hydrochloride is now commercially available to customers in Europe and other global markets with mutual recognition of the CEP.
-
Brochure C2 PHARMA Recevies CEP for Tropicamide
C2P receives the approval of a Certificate of Suitability (CEP) for Tropicamide by the European Directorate for the Quality of Medicines and Health Care (EDQM). -
News C2 PHARMA Expands Ophthalmic API Portfolio with Naphazoline Hydrochloride Launch
C2 PHARMA, a global provider of ophthalmic and niche active pharmaceutical ingredients (APIs), has launched its latest API, Naphazoline Hydrochloride. The validation campaign for Naphazoline HCL was completed in June 2024. A Certificate of Suitability (CEP) is under approval while the US-Drug Master File (US-DMF) is planned for submission by November 2024 and the API dossier for Brazil (DIFA) in December 2024. -
Brochure C2 PHARMA's Upcoming Launch of Oxybuprocaine Hydrochloride
C2P is excited to announce the upcoming launch of their new API, Oxybuprocaine HCL, an API that will be manufactured by our manufacturing partner Laurus Labs. -
News C2 PHARMA Receives CEP Approval For Tropicamide
C2 PHARMA the global leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the approval of a Certificate of Suitability (CEP) for Tropicamide by the European Directorate for the Quality of Medicines and Health Care (EDQM). This is the first Tropicamide CEP for a European-based company, allowing C2 PHARMA to make the API commercially accessible to customers globally. -
Brochure C2 PHARMA Expands Ophthalmic API Portfolio with Naphazoline Hydrochloride Launch
C2 PHARMA has added a new ophthalmic API to their portfolio, Naphazoline Hydrochloride. GMP samples are ready for customers worldwide. -
News C2 PHARMA’S Upcoming Launch of Oxybuprocaine Hydrochloride
C2 Pharma is excited to announce the upcoming launch of their new Ophthalmic API, Oxybuprocaine Hydrochloride. To learn more check out the full press release. -
Brochure C2 PHARMA & Affiliate Company
Your API Manufacturing Partner and Affiliate companie.
Get to know a bit about why you should work with us and what we have to offer. -
News C2 PHARMA Expands API Portfolio with Global Regulatory Access Ahead of CPHI Barcelona
C2 PHARMA has expanded their API portfolio global access with new regulatory submissions and approvals, a pending new product launch and have signed on a new CMO, SMS Lifesciences.
-
Video Your Leader in Ophthalmic APIs
C2 PHARMA is a European pharmaceutical group established in 2014.
It manufactures and distributes active pharmaceutical ingredients
(APls) and complex chemical compounds obtained from synthetic and
natural origins. C2 PHARMA is today the global leader in ophthalmic APIs.
-
News Affiliate Company Logistics4Pharma Expands GDP-Bonding Warehouse Services
Press release about C2 PHARMA's affiliate company Logistics4PHARMAs move and expansion of their GDP Bonded Warehouse to Kelsterbach, Germany. -
Video Ophthalmic Buyers Guide x PharmaSource
As the global leader in Ophthalmic APIs, C2 PHARMA was asked to participate in Pharmasource’s buyer guide focused on Ophthalmics. We go to show our expertise and share a bit about our company and product portfolio. -
News EDQM Grants C2 PHARMA CEP Approval for Commercial Sale of Cyclopentolate Hydrochloride
C2 Pharma receives the European Directorate for the Quality of Medicines and Healthcare second Certificate of Suitability for Cyclopentolate Hydrochloride, a significant achievement for our dedicated team. -
.png)
Video Leader in Ophthalmic & Niche APIs
A quick portfolio review of what we have to offer as your global leader in Ophthalmic APIs. -
Industry Podcast C2 Pharma: The World’s Leading Manufacturer of Ophthalmic APIs
PharmaSource's Supplier Spotlight podcast series featuring Senior Manager of Business Development Serge Tarabay talk about C2 PHARMA's rise to becoming the Global Leader in Ophthalmic APis. -
Brochure C2 PHARMA Digoxin China DMF Approved, Becoming China's Only European Supplier
Press release covering our approval by the CDE of a C-DMF for Digoxin, becoming China’s only European supplier of this API. The approval covers both digoxin and digoxin micronized, and it supports different dosage forms, i.e., oral and injectable drug product formulations. -
Brochure Our Affiliate Logistics4Pharma, Featured Article "A Road Map to Greener Pharma Logistics"
This article highlights the power of internal change for a greener future. From packaging to transportation, every logistics company has the opportunity to make a difference, and Logistics4Pharma's Head of Supply Chain & Finance and Head of Operations and Customer Service give their expertise and opinions on how to become greener for the future of pharmaceutical logistics. -
Brochure CEO Deep Dive with Cleanroom Technology
A featured interview with CEO of C2 PHARMA, Andrew Badrot, where he discusses his journey to starting the company and its affiliates, along with the importance of quality and quality relationships.